[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100464871":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":58,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":20,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Gangnam Severance Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"OFS with endocrine","EXPERIMENTAL","Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, the patients with a genomic low risk using the multigene-assay (OncoFREE®) will be included in this arm.",[13],"Drug: Ovarian function suppression with endocrine treatments",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ovarian function suppression with endocrine treatments","* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.\n* Either goserelin acetate or leuprorelin Acetate is allowed.\n* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.\n* Chemotherapy is omitted in these patients.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Sung Gwe Ahn, M.D.,Ph.D.","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","0220193370","asg2004@yuhs.ac",[31,49],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":20,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Seoul","Korea","06229","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},[44,46,47],{"name":45,"role":27,"phone":28,"phoneExt":20,"email":29},"Sung Gwe Ahn, MD, PhD",{"name":20,"role":27,"phone":20,"phoneExt":20,"email":29},{"name":48,"role":24,"phone":20,"phoneExt":20,"email":20},"Sung Gwe Ahn, MD.,PH.D.",{"facility":50,"status":51,"city":33,"state":20,"zip":20,"country":36,"countryCode":20,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"Seoul National University Hospital","NOT_YET_RECRUITING",{"type":38,"coordinates":53},[40,41],{"lat":41,"lon":40},[56],{"name":57,"role":27,"phone":20,"phoneExt":20,"email":20},"Hyeoung Gon Moon",{"type":24,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Sung Gwe Ahn","Associated Professor",[62],{"name":63,"class":6},"Seoul National University","100464871","phase-4-ofs-in-premenopausal-node-breast-cancer-with-low-genomic-risk-100464871",false,"NCT05333328","OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk","Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node+ Early Breast Cancer With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)","INTERSTELLAR","Inclusion Criteria:\n\n* ER+HER2- breast cancer\n* Premenopausal and age \\\u003C=50\n* T1 or T2\n* N1 including micrometastasis\n* Genomic Low Risk by OncoFREE test® (1-20)\n\nExclusion Criteria:\n\n* Postmenopausal women\n* ER-negative breast cancer","FEMALE","20 Years","50 Years",{"count":76,"type":77},418,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).\n\nIn these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.",[83,84,85,86,87],"Breast Cancer","Estrogen Receptor Positive Tumor","HER2-negative Breast Cancer","Premenopausal Breast Cancer","Node-positive Breast Cancer",[83,84,85,86,87,89,90],"Multigene assay","Ovarian-function suppression","2025-05-18",{"date":93,"type":94},"2025-05-22","ACTUAL",{"date":96,"type":94},"2023-02-06",{"date":98,"type":77},"2033-01",{"name":5,"class":6},2]